​

Marker Therapeutics (MRKR) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Marker Therapeutics Revenue Highlights

Latest Revenue (Y)

$6.59T

Latest Revenue (Q)

$1.93M

Main Segment (Y)

Grant

Marker Therapeutics Revenue by Period

Marker Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$6.59T199058047.17%
2023-12-31$3.31M-63.23%
2022-12-31$9.00M625.17%
2021-12-31$1.24M166.01%
2020-12-31$466.79K118.95%
2019-12-31$213.19K3.50%
2018-12-31$205.99K12.53%
2017-12-31$183.06K100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31-100.00%
2010-12-31-100.00%
2009-12-31-100.00%
2008-12-31-100.00%
2007-12-31-100.00%
2006-12-31-100.00%
2005-12-31-100.00%
2004-12-31-100.00%
2003-12-31-100.00%
2002-12-31-100.00%
2001-12-31--100.00%
2000-12-31$25.05K-79.25%
1999-12-31$120.72K-

Marker Therapeutics generated $6.59T in revenue during NA 2024, up 199058047.17% compared to the previous quarter, and up 3091587943.38% compared to the same period a year ago.

Marker Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$1.93M64.72%
2024-06-30$1.17M-6.01%
2024-03-31$1.24M17.75%
2023-12-31$1.06M310.13%
2023-09-30$257.61K-66.22%
2023-06-30$762.66K-78.21%
2023-03-31$3.50M-42.19%
2022-12-31$6.05M105.24%
2022-09-30$2.95M272.95%
2022-06-30$791.00K-17.95%
2022-03-31$964.00K-22.37%
2021-12-31$1.24M100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31--100.00%
2020-12-31$215.00100.00%
2020-09-30--100.00%
2020-06-30$466.79K100.00%
2020-03-31--100.00%
2019-12-31$213.19K100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--100.00%
2018-12-31$6.00100.00%
2018-09-30--100.00%
2018-06-30$205.99K100.00%
2018-03-31-100.00%
2017-12-31--100.00%
2017-09-30$183.06K100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-10-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2011-12-31-100.00%
2011-09-30-100.00%
2011-06-30-100.00%
2011-03-31-100.00%
2010-12-31-100.00%
2010-09-30-100.00%
2010-06-30-100.00%
2010-03-31-100.00%
2009-12-31-100.00%
2009-09-30-100.00%
2009-06-30-100.00%
2009-03-31-100.00%
2008-12-31-100.00%
2008-09-30-100.00%
2008-06-30-100.00%
2008-03-31-100.00%
2007-12-31--

Marker Therapeutics generated $1.93M in revenue during Q3 2024, up 64.72% compared to the previous quarter, and up 252.54% compared to the same period a year ago.

Marker Therapeutics Revenue Breakdown

Marker Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
Grant$6.59M$3.51M$466.79K--
Service-$816.64K$5.50M--
Related Party Service-$3.50M---
Grant income---$1.24M-

Marker Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Grant (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Jun 24Mar 24Dec 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 19
Grant$2.25M$1.93M$1.17M$1.24M$1.23M$759.14K$999.57K$213.19K---
Service-----$3.50M$2.55M----
Grant income--------$790.51K$964.32K-

Marker Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Grant (100.00%).

Marker Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 23Dec 22Sep 22Jun 22Mar 22Dec 19
Service$3.50M$2.55M----
Grant$1.23M$759.14K$999.57K$213.19K--
Grant income---$790.51K$964.32K-

Marker Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Service (73.93%), and Grant (26.07%).

Marker Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
MRKRMarker Therapeutics$6.59T$1.93M
AGENAgenus$103.46M$25.11M
ALECAlector$100.56M$15.08M
AADIAadi Bioscience$25.98M$7.21M
KROSKeros Therapeutics$3.55M$37.00K
XCURExicure$500.00K-
RNXTRenovoRx$43.00K-
IKNAIkena Oncology--
ANEBAnebulo Pharmaceuticals--
EWTXEdgewise Therapeutics--
AVTEAerovate Therapeutics--
TPSTTempest Therapeutics--
ACRVAcrivon Therapeutics--
PMVPPMV Pharmaceuticals--
PTIXProtagenic Therapeutics-$50.29K

MRKR Revenue FAQ

What is Marker Therapeutics’s yearly revenue?

Marker Therapeutics's yearly revenue for 2024 was $6.59T, representing an increase of 199058047.17% compared to 2023. The company's yearly revenue for 2023 was $3.31M, representing a decrease of -63.23% compared to 2022. MRKR's yearly revenue for 2022 was $9M, representing an increase of 625.17% compared to 2021.

What is Marker Therapeutics’s quarterly revenue?

Marker Therapeutics's quarterly revenue for Q3 2024 was $1.93M, a 64.72% increase from the previous quarter (Q2 2024), and a 647.66% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.17M, a -6.01% decrease from the previous quarter (Q1 2024), and a 53.31% increase year-over-year (Q2 2023). MRKR's quarterly revenue for Q1 2024 was $1.24M, a 17.75% increase from the previous quarter (Q4 2023), and a -64.46% decrease year-over-year (Q1 2023).

What is Marker Therapeutics’s revenue growth rate?

Marker Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 73197279.54%, and for the last 5 years (2020-2024) was 1412016138.74%.

What are Marker Therapeutics’s revenue streams?

Marker Therapeutics's revenue streams in c 24 are Grant

What is Marker Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Marker Therapeutics was Grant. This segment made a revenue of $6.59M, representing 100.00% of the company's total revenue.